Finance entity
All 1 tracked stories fall under one category: earnings. BBOT is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 5 original sources per story, versus 2.9 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. BBOT is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 5 original sources per story, versus 2.9 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. We currently track 1 Finance story that mention Atea Pharmaceuticals, all published on March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 98 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Atea Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
A cluster of mid-cap and small-cap companies, led by Rumble and Atea Pharmaceuticals, released fourth-quarter and full-year 2025 results, signaling a period of strategic transition. The reports highlight a divergence between high-growth digital infrastructure and the clinical-stage healthcare sector as firms navigate the post-2024 economic landscape.
Atea Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
